Development of a Physiologically Based Pharmacokinetic (PBPK) Simulation Model for Nicotine

Area of Science:

• Pharmacology
• Toxicology
• Public Health

Background:

• Tobacco use causes chronic diseases globally.
• Nicotine is addictive and poses health risks, especially to cardiovascular and pulmonary systems.
• Electronic Nicotine Delivery Systems (ENDS) impact requires evaluation.

Purpose of the Study:

• Develop and validate a physiologically based pharmacokinetic (PBPK) simulation model for nicotine.
• Utilize clinical pharmacokinetic data for model development.
• Assess nicotine's pharmacokinetic behavior across different administration routes.

Main Methods:

• Incorporated drug-specific and system-specific parameters into the PBPK model.
• Modeled nicotine's absorption, distribution, metabolism, and excretion (ADME).
• Validated the model using clinical data from intravenous and pulmonary administration routes.

Main Results:

• The PBPK model accurately predicted plasma nicotine concentrations.
• Predicted pharmacokinetic parameters (Cmax, Tmax, AUCs) were within acceptable ranges of observed values.
• The model demonstrated computational average fold error values.

Conclusions:

• The validated PBPK model is a practical tool for assessing nicotine exposure.
• The model supports dose optimization and safety margin quantification.
• Informs safer product design and public health regulatory science decisions.